Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ANTICONFLICT EFFECTS OF A COMPETITIVE NMDA RECEPTOR ANTAGONIST AND A PARTIAL AGONIST AT STRYCHNINE-INSENSITIVE GLYCINE RECEPTORS
Autore:
PRZEGALINSKI E; TATARCZYNSKA E; DERENWESOLEK A; CHOJNACKAWOJCIK E;
Indirizzi:
POLISH ACAD SCI,INST PHARMACOL,12 SMETNA ST PL-31343 KRAKOW POLAND
Titolo Testata:
Pharmacology, biochemistry and behavior
fascicolo: 1, volume: 54, anno: 1996,
pagine: 73 - 77
SICI:
0091-3057(1996)54:1<73:AEOACN>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
ELEVATED PLUS-MAZE; PHENCYCLIDINE-LIKE; ANXIOLYTIC ACTIVITY; SOCIAL-INTERACTION; RHESUS-MONKEYS; ANIMAL-MODELS; BINDING-SITES; ACID; MK-801; BRAIN;
Keywords:
CGP 37849; 1-AMINOCYCLOPROPANECARBOXYLIC ACID; DRINKING CONFLICT TEST; PERIPHERAL ADMINISTRATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
46
Recensione:
Indirizzi per estratti:
Citazione:
E. Przegalinski et al., "ANTICONFLICT EFFECTS OF A COMPETITIVE NMDA RECEPTOR ANTAGONIST AND A PARTIAL AGONIST AT STRYCHNINE-INSENSITIVE GLYCINE RECEPTORS", Pharmacology, biochemistry and behavior, 54(1), 1996, pp. 73-77

Abstract

Using the conflict drinking Vogel test in rats as a model, in the present study we examined the anxiolytic-like activity of DL-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (CGP 37849), a competitive N-methyl-D-aspartate (NMDA) receptor antagonist and 1-aminocyclopropanecarboxylic acid (ACPC), a partial agonist at strychnine-insensitive glycine receptors associated with the NMDA receptor complex, after their intraperitoneal (IP) and intrahippocampal (IHP) administration. CGP 37849, administered in doses of 1.25-5 mg/kg IP, produced an anticonflict effect in a dose-dependent manner, but was inactive when injected in doses of 0.01-0.1 mu g IHP. At the same time, when administered in higher doses (10 mg/kg IP or 0.3 mu g IHP), that drug induced motor impairment. On the other hand, ACPC exhibited an anxiolytic-like activity after both IP (100-200 mg/kg) and IHP (3-30 mu g) administration. These results, as well as the literature data on the lack of motor-impairing effects of ACPC, indicate that the latter drug seems to be more advantageous than CGP 37849 as a potential therapeutic agent in the treatment of anxiety disorders. Furthermore, they also show that the hippocampus may be one of the neuroanatomical sites of the anxiolytic-like effect of ACPC, but not of CGP 37849.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 00:26:30